Spots Global Cancer Trial Database for allogeneic transplant
Every month we try and update this database with for allogeneic transplant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation | NCT02893189 | CD19+ Malignanc... | Infusion of mod... | 16 Years - 70 Years | University College, London | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey. | NCT05352789 | Haematological ... Bone Marrow Tra... Stem Cell Trans... Nutrition Aspec... Nutritional and... Exercise Interv... Prehabilitation | Non validated S... | 18 Years - | Nottingham University Hospitals NHS Trust | |
| A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia | NCT01814488 | Acute Leukemia | allogeneic tran... | 18 Years - 70 Years | Gruppo Italiano Trapianto di Midollo Osseo | |
| Nonmyeloablative Allogeneic Transplant | NCT01272817 | Aplastic Anemia Paroxysmal Noct... Acute Myelogeno... Acute Lymphocyt... Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Hodgkin's Lymph... Non-Hodgkin's L... Mantle Cell Lym... Multiple Myelom... Waldenstrom Mac... Breast Cancer Renal Cell Carc... Melanoma Sarcoma Ovarian Cancer Thymoma | Nonmyeloablativ... Nonmyeloablativ... | 18 Years - 72 Years | Scripps Health | |
| Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma | NCT00670410 | Neuroblastoma | Related donor t... Cord blood tran... Busulfan Thymoglobulin Fludarabine | - 30 Years | Columbia University | |
| Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants | NCT01881334 | Hematologic Mal... Inborn Errors o... Immune Deficien... | CliniMACS CD34 ... | - 65 Years | Duke University | |
| Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | NCT02065154 | Leukemia Lymphoma Myelodysplastic... Myelofibrosis Severe Aplastic... Allogeneic Tran... | Cyclophosphamid... | 19 Years - 65 Years | University of Alabama at Birmingham | |
| Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey. | NCT05352789 | Haematological ... Bone Marrow Tra... Stem Cell Trans... Nutrition Aspec... Nutritional and... Exercise Interv... Prehabilitation | Non validated S... | 18 Years - | Nottingham University Hospitals NHS Trust | |
| Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | NCT02065154 | Leukemia Lymphoma Myelodysplastic... Myelofibrosis Severe Aplastic... Allogeneic Tran... | Cyclophosphamid... | 19 Years - 65 Years | University of Alabama at Birmingham | |
| Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults | NCT00327678 | Leukemia, Lymph... | Rituximab Imatinib Mesyla... | 18 Years - 59 Years | Assistance Publique - Hôpitaux de Paris | |
| Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) | NCT00096460 | Recurrent Grade... Recurrent Grade... Recurrent Grade... Follicular Lymp... | Cyclophosphamid... Filgrastim Chemotherapy or... Non-myeloablati... Allogeneic tran... Autologous tran... Rituximab maint... GVHD Prophylaxi... | - 75 Years | Medical College of Wisconsin | |
| Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies | NCT00460694 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Non Hodgkin's L... Hodgkin's Disea... Myelodysplastic... Multiple Myelom... | infusion of all... | 12 Years - 60 Years | Singapore General Hospital | |
| CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation | NCT02893189 | CD19+ Malignanc... | Infusion of mod... | 16 Years - 70 Years | University College, London | |
| Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV | NCT01535885 | Epstein-Barr Vi... Adenovirus Cytomegalovirus... | Cytotoxic T Lym... | - 22 Years | Medical College of Wisconsin | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation | NCT04496011 | Fatigue Leukemia Lymphoma Multiple Myelom... Hematopoietic S... | Aerobic trainin... | 18 Years - 70 Years | Federal University of Health Science of Porto Alegre |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
